FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120228520> ?p ?o ?g. }

• W3120228520 endingPage "3675" @default.
• W3120228520 startingPage "3658" @default.
• W3120228520 abstract "Infectious bursal disease (IBD) is one of the most economically important infectious diseases. Currently, vaccination is the most effective method to prevent IBD. Medium-virulence vaccines can damage the bursa of Fabricius and result in immunosuppression. Therefore, it is essential to develop a safe and effective vaccine against infectious bursal disease virus (IBDV). In this study, the five neutralizing epitopes of the IBDV VP2 protein were confirmed by neutralizing single chain variable fragment antibodies. Then, the neutralizing epitopes antigen (NEA) protein was constructed with five neutralizing epitopes and expressed by pET-27b. Furthermore, the immune effect and protective immunity of the NEA protein with the following adjuvants were evaluated in specific-pathogen-free chickens: oil emulsion adjuvant (OEA), double emulsion adjuvant (DEA), granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant and complete Freund's adjuvant (CFA). The experimental results demonstrated that chickens immunized with NEA vaccines elicited stronger humoral and/or cellular immune responses and inflammatory responses than those in the NEA protein group. Chickens were protected in OEA, CFA and GM-CSF adjuvant groups, which were challenged with virulent IBDV BC6/85. Furthermore, IBDV RNA was not measured, and there appeared to be little apoptosis in the bursa of Fabricius based on TUNEL histology and the expression of Bax and Bcl-2 in the OEA, CFA and GM-CSF adjuvant groups. Based on the experimental results, the advantages and disadvantages of adjuvants and industrial production methods, GM-CSF was found to be the optimal adjuvant. Therefore, NEA with GM-CSF adjuvant is a promising vaccine candidate against IBDV, and it provides a framework for developing other vaccines against infectious viral diseases." @default.
• W3120228520 created "2021-01-18" @default.
• W3120228520 creator A5020943526 @default.
• W3120228520 creator A5037144721 @default.
• W3120228520 creator A5047146848 @default.
• W3120228520 creator A5048761040 @default.
• W3120228520 creator A5051905686 @default.
• W3120228520 creator A5058822766 @default.
• W3120228520 creator A5061867449 @default.
• W3120228520 creator A5064505506 @default.
• W3120228520 creator A5065236570 @default.
• W3120228520 creator A5065912071 @default.
• W3120228520 creator A5066378778 @default.
• W3120228520 creator A5075921353 @default.
• W3120228520 creator A5084951844 @default.
• W3120228520 creator A5091148268 @default.
• W3120228520 date "2021-01-29" @default.
• W3120228520 modified "2023-09-23" @default.
• W3120228520 title "Development and evaluation of a recombinant VP2 neutralizing epitope antigen vaccine candidate for infectious bursal disease virus" @default.
• W3120228520 cites W1802870181 @default.
• W3120228520 cites W1978065270 @default.
• W3120228520 cites W1979587529 @default.
• W3120228520 cites W1980605992 @default.
• W3120228520 cites W1984604499 @default.
• W3120228520 cites W1984655673 @default.
• W3120228520 cites W1984787094 @default.
• W3120228520 cites W1988078082 @default.
• W3120228520 cites W1990933870 @default.
• W3120228520 cites W1997117545 @default.
• W3120228520 cites W2013887826 @default.
• W3120228520 cites W2023520581 @default.
• W3120228520 cites W2027201675 @default.
• W3120228520 cites W2029606923 @default.
• W3120228520 cites W2029884055 @default.
• W3120228520 cites W2041397637 @default.
• W3120228520 cites W2042835129 @default.
• W3120228520 cites W2045507680 @default.
• W3120228520 cites W2045954345 @default.
• W3120228520 cites W2047938746 @default.
• W3120228520 cites W2053388247 @default.
• W3120228520 cites W2053739051 @default.
• W3120228520 cites W2059494914 @default.
• W3120228520 cites W2069485883 @default.
• W3120228520 cites W2072471168 @default.
• W3120228520 cites W2074065268 @default.
• W3120228520 cites W2075779452 @default.
• W3120228520 cites W2083407483 @default.
• W3120228520 cites W2088002180 @default.
• W3120228520 cites W2090178972 @default.
• W3120228520 cites W2092282307 @default.
• W3120228520 cites W2099619575 @default.
• W3120228520 cites W2102053035 @default.
• W3120228520 cites W2105580210 @default.
• W3120228520 cites W2106588028 @default.
• W3120228520 cites W2109003578 @default.
• W3120228520 cites W2120404094 @default.
• W3120228520 cites W2144887013 @default.
• W3120228520 cites W2172466148 @default.
• W3120228520 cites W2323542703 @default.
• W3120228520 cites W2328292833 @default.
• W3120228520 cites W2345713210 @default.
• W3120228520 cites W2519529807 @default.
• W3120228520 cites W2900829177 @default.
• W3120228520 cites W2985904101 @default.
• W3120228520 cites W352853897 @default.
• W3120228520 doi "https://doi.org/10.1111/tbed.13974" @default.
• W3120228520 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33406318" @default.
• W3120228520 hasPublicationYear "2021" @default.
• W3120228520 type Work @default.
• W3120228520 sameAs 3120228520 @default.
• W3120228520 citedByCount "5" @default.
• W3120228520 countsByYear W31202285202021 @default.
• W3120228520 countsByYear W31202285202022 @default.
• W3120228520 countsByYear W31202285202023 @default.
• W3120228520 crossrefType "journal-article" @default.
• W3120228520 hasAuthorship W3120228520A5020943526 @default.
• W3120228520 hasAuthorship W3120228520A5037144721 @default.
• W3120228520 hasAuthorship W3120228520A5047146848 @default.
• W3120228520 hasAuthorship W3120228520A5048761040 @default.
• W3120228520 hasAuthorship W3120228520A5051905686 @default.
• W3120228520 hasAuthorship W3120228520A5058822766 @default.
• W3120228520 hasAuthorship W3120228520A5061867449 @default.
• W3120228520 hasAuthorship W3120228520A5064505506 @default.
• W3120228520 hasAuthorship W3120228520A5065236570 @default.
• W3120228520 hasAuthorship W3120228520A5065912071 @default.
• W3120228520 hasAuthorship W3120228520A5066378778 @default.
• W3120228520 hasAuthorship W3120228520A5075921353 @default.
• W3120228520 hasAuthorship W3120228520A5084951844 @default.
• W3120228520 hasAuthorship W3120228520A5091148268 @default.
• W3120228520 hasBestOaLocation W31202285201 @default.
• W3120228520 hasConcept C104317684 @default.
• W3120228520 hasConcept C147483822 @default.
• W3120228520 hasConcept C159047783 @default.
• W3120228520 hasConcept C159654299 @default.
• W3120228520 hasConcept C195616568 @default.
• W3120228520 hasConcept C196978929 @default.
• W3120228520 hasConcept C203014093 @default.
• W3120228520 hasConcept C22070199 @default.

• next